Why the study?
Does antithyroid treatment normalize cardiac performance in patients with hyperthyroidism?
Does antithyroid treatment normalize cardiac performance in patients with hyperthyroidism?
Antithyroid treatment, but not beta-blockers alone, normalizes hypercontractility in hyperthyroidism, suggesting mechanisms beyond increased sympathoadrenal drive.
Answers are grounded in this paper and cite their sources.
May support prioritizing antithyroid therapy for cardiac effects in hyperthyroidism; hypothesis-generating for mechanisms beyond sympathoadrenal drive.
Systolic time intervals (STI) and radionuclide ventriculography (RNV) were used in the assessment of cardiac performance in 22 patients with hyperthyroidism before and after antithyroid treatment. STI as well as RNV showed enhanced myocardial contractility which was normalized after antithyroid treatment. Beta-blocker treatment did not influence the hypercontractility in hyperthyroidism. This implies that beta-blockers alone cannot be regarded as satisfactory long-term treatment and that mechanisms other than increased sympathoadrenal drive are involved in the hypercontractility in hyperthyroidism. RNV suggested valvular regurgitation, probably of the mitral valve, in 11 patients. Possible hemodynamic consequences are discussed.
No takes yet. Share an insight, caveat, or question.
Mangschau et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: